Amunix Pharmaceuticals
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing innovative protein and peptide therapeutics for cancer treatment. The company utilizes its proprietary XTEN platform for half-life extension, the XPAT platform for analyzing protease activity in the tumor microenvironment, and the Protease Triggered Immune Activator (ProTIA) for immuno-oncology therapies. Amunix aims to provide transformative T-cell engagers and cytokine therapies, addressing unmet medical needs in oncology. Its strategic partnerships with industry leaders enhance its capability to advance its pipeline of immuno-oncology products. Founded in 2006 and headquartered in Mountain View, California, Amunix Pharmaceuticals serves the academic, biotechnology, and pharmaceutical sectors, leveraging its clinically validated technologies to develop novel biologics for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.